Market Performance - On April 17, 2025, the pharmaceutical sector had a change of +0.04%, outperforming the CSI 300 index by 0.06 percentage points, ranking 16th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, medical devices (+0.98%), pharmaceutical distribution (+0.40%), and offline pharmacies (+0.35%) performed well, while other bioproducts (-0.57%), vaccines (-0.48%), and blood products (-0.22%) lagged [1] - Top three gainers in individual stocks were Kangpeng Technology (+20.00%), Nuosige (+10.06%), and Yisheng Pharmaceutical (+10.03%); top three losers were Changyao Holdings (-6.33%), Hasanlian (-5.26%), and Shouyao Holdings (-4.81%) [1] Industry News - On April 17, 2025, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved statistically significant positive results in a key Phase III clinical trial (ACHIEVE-1) [2] - The study evaluated the safety and efficacy of Orforglipron compared to a placebo in adults with type 2 diabetes who had poor blood sugar control through diet and exercise alone [2] - Orforglipron is a research-based, once-daily oral small molecule (non-peptide) GLP-1 receptor agonist that can be taken at any time of the day without food and drink restrictions [2] Company News - Huayuan Bio (300401) reported Q1 2025 revenue of 326 million yuan, a year-on-year decrease of 1.18%, with net profit attributable to the parent company at 97 million yuan, a year-on-year increase of 5.50%, and a non-recurring net profit of 88 million yuan, up 44.42% year-on-year [3] - Puluo Pharmaceutical (000739) reported Q1 2025 revenue of 2.73 billion yuan, a year-on-year decrease of 14.63%, with net profit attributable to the parent company at 249 million yuan, a year-on-year increase of 1.98%, and a non-recurring net profit of 206 million yuan, down 14.05% year-on-year [3] - Sanbo Brain Science (301293) reported 2024 revenue of 1.43 billion yuan, a year-on-year increase of 8.84%, with net profit attributable to the parent company at 105 million yuan, a year-on-year increase of 34.24%, and a non-recurring net profit of 94 million yuan, up 0.77% year-on-year [3] - Betta Pharmaceuticals (300558) reported 2024 revenue of 2.89 billion yuan, a year-on-year increase of 17.74%, with net profit attributable to the parent company at 403 million yuan, a year-on-year increase of 15.67%, and a non-recurring net profit of 410 million yuan, up 55.92% year-on-year [3]

花园生物：2025年第一季度净利润9651.14万元，同比增长5.50%。 ...

Group 1 - The vitamin sector experienced a decline of 1.97% on April 16, with a net outflow of 183 million yuan from main funds, where 4 stocks rose and 26 stocks fell [1] - The companies with the highest net outflow of main funds included China Resources Sanjiu (588.49 million yuan), Xingqi Eye Medicine (313.44 million yuan), Shengda Biology (188.84 million yuan), North China Pharmaceutical (183.74 million yuan), and Nengte Technology (181.81 million yuan) [1] Group 2 - The top stock by net inflow was Huayuan Biological, with a net inflow of 32.28 million yuan and a price increase of 0.29% [2] - New Hec (21.80 yuan) saw a decline of 1.71% with a net inflow of 16.02 million yuan, while Brother Technology (4.02 yuan) experienced a significant drop of 6.07% with a net inflow of 9.80 million yuan [2] - Other notable declines included Zhejiang Medicine (-1.23%), Hendi Pharmaceutical (-1.37%), and Weixin Kang (-1.80%), all showing negative net inflows [2]

浙江花园生物医药股份有限公司 1.公司 25-羟基维生素 D3 结晶设计产能 15.6 吨/年，25-羟基维生素 D3 原设计产能 26 吨/年，25-羟基维生素 D3 粉设计产能 1200 吨/年。2.25- 羟基维生素 D3 又名骨化二醇，是维生素 D3 的活性代谢物，具有更高的生 物学活性，并且不需要经过肝脏的代谢，25-羟基维生素 D3 不仅具有普通 维生素 D3 所有的功能，还具有一些独特功能，25-羟基维生素 D3 具有替代 普通维生素 D3 的趋势。3.下游主要用于饲料添加剂、食品添加剂等。 66、公司近年来通过非公开发行股票和可转换公司债券等方式进行了 多次募投项目的进展如何？特别是"花园生物研发中心项目"和"年 产 4000 吨胆钙化醇（维生素 D3）环保杀鼠剂项目"的当前状态及未 来规划？ 投资者关系活动记录表 | 证券代码：300401 | 证券简称：花园生物 编号：2025-001 | | --- | --- | | | □特定对象调研 □ 分析师会议 | | 投资者关系活动 | □ 媒体采访 √ 业绩说明会 | | 类别 | 新闻发布会 路演活动 □ □ | | | □ 现场参观 □ ...

Investment Rating - The report maintains an "Accumulate" rating for the company [6] Core Views - The company has shown a recovery in performance and is actively expanding into new business areas [1] - The vitamin product segment is expected to recover, while the pharmaceutical segment remains under pressure [9] - The company is implementing a "vertical and horizontal" strategy to expand its business and new product offerings [9] Financial Performance Summary - The company's revenue for 2023 was 1,095 million, with a projected increase to 1,243 million in 2024, representing a year-on-year growth of 13.6% [5] - Operating profit is expected to rise from 207 million in 2023 to 355 million in 2024, reflecting a significant growth of 71.6% [5] - Net profit attributable to the parent company is forecasted to increase from 192 million in 2023 to 309 million in 2024, a growth of 60.8% [5] - Earnings per share are projected to grow from 0.35 in 2023 to 0.57 in 2024 [5] - The gross margin is expected to be 58.4% in 2024, with a net margin of 24.9% [5] Earnings Forecast and Investment Recommendations - The report adjusts revenue forecasts for vitamin products and pharmaceuticals while increasing the gross margin for vitamin products [3] - The projected earnings per share for 2025-2027 are 0.88, 1.05, and 1.36 respectively [3] - Based on comparable companies, a target price of 14.96 is set for 2025, corresponding to a 17 times price-to-earnings ratio [3]

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [13]. Core Views - The pharmaceutical sector experienced a decline of 0.84% on March 24, 2025, underperforming the CSI 300 index by 1.35 percentage points, ranking 21st among 31 sub-industries [5]. - Notable performances within sub-industries include vaccines (+0.17%) and medical research outsourcing (-0.16%), while hospitals (-2.17%) and medical devices (-1.35%) lagged [5]. - Alnylam's RNAi therapy Vutrisiran has received FDA approval for treating wild-type or hereditary ATTR-CM in adults, aimed at reducing cardiovascular mortality and hospitalizations [6]. Summary by Sections Market Performance - On March 24, 2025, the pharmaceutical sector's performance was -0.84%, underperforming the CSI 300 index by 1.35% [5]. - The top three gainers were Tianyu Co. (+9.95%), Zhongyuan Qihe (+8.82%), and Shanwaishan (+6.60%), while the largest decliners were Aipeng Medical (-10.22%), Innovation Medical (-9.97%), and Sanbo Brain Science (-8.99%) [5]. Industry News - Alnylam announced FDA approval for Vutrisiran, a subcutaneous RNAi therapy targeting specific mRNA to block the production of transthyretin protein, enhancing efficacy and metabolic stability [6]. - Garden Biologics reported a 13.58% year-on-year increase in revenue to 1.243 billion yuan for 2024, with a net profit growth of 60.76% to 309 million yuan [7]. - Shouxiangu reported a 10.87% decline in revenue to 699 million yuan for 2024, with a net profit decrease of 27.87% to 184 million yuan [7].

花园生物:2024年报净利润3.09亿 同比增长60.94% 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.5700 | 0.3500 | 62.86 | 0.7000 | | 每股净资产（元） | 0 | 4.77 | -100 | 4.67 | | 每股公积金(元) | -0.1 | -0.01 | -900 | -0.07 | | 每股未分配利润(元) | 4.15 | 3.65 | 13.7 | 3.48 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 12.43 | 10.95 | 13.52 | 14.18 | | 净利润(亿元) | 3.09 | 1.92 | 60.94 | 3.84 | | 净资产收益率(%) | 10.17 | 7.30 | 39.32 | 15.89 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1]. Core Insights - The global new drug business development (BD) remains robust, with approximately 31% of innovative drug candidates introduced by multinational pharmaceutical companies in 2024 coming from China. In the first two months of 2025, there have already been 16 Chinese innovative drug BD projects, expanding from oncology to autoimmune diseases [3]. - The weight loss market is seeing multiple BD agreements, with significant sales figures reported by Novo Nordisk and Eli Lilly. Novo Nordisk's core products generated sales of approximately $27.94 billion in 2024, while Eli Lilly's Mounjaro saw a 124% year-on-year increase in sales to $11.54 billion [5]. - CAR-T cell therapy continues to progress, with global sales expected to reach approximately $4.53 billion in 2024. Chinese companies are also participating in the global CAR-T sales, indicating their technological capabilities [6]. - The gene sequencing industry is accelerating its domestic production capabilities following export restrictions on Illumina's sequencing instruments. Domestic alternatives are rapidly emerging, with several companies receiving regulatory approvals for their sequencing devices [7]. - AI in healthcare is advancing, with various AI models being developed for specific medical fields. Collaborations between tech companies and healthcare providers are enhancing the integration of AI into traditional medical practices [9]. Summary by Sections Industry Trends - The pharmaceutical industry outperformed the CSI 300 index by 0.18 percentage points in the past week, with a weekly increase of 1.77% [23]. - Over the past month, the pharmaceutical sector also outperformed the CSI 300 index by 0.22 percentage points, with a monthly increase of 1.94% [27]. Subsector Performance - The pharmaceutical commercial sector saw the highest weekly increase of 6.44%, while the medical device sector had the lowest at 1.09% [30]. - Over the past year, the chemical pharmaceutical sector had the highest increase of 6.49%, while the biological products sector experienced a decline of 17.62% [37]. Company Recommendations - The report recommends focusing on companies involved in weight loss and NASH, such as Zhongsheng Pharmaceutical, and highlights the potential of companies like Geli Pharmaceutical and Lianbang Pharmaceutical [12]. - Companies engaged in CAR-T technology, such as Kexin Pharmaceutical, are also recommended as they approach market entry [12]. - The report emphasizes the importance of AI integration in medical devices, recommending companies like Anbiping and RunDa Medical for their competitive advantages [12]. Recent Developments - The report notes significant recent financing and regulatory approvals for various companies, indicating a dynamic and evolving market landscape [54][55].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [4]. Core Views - The government has increased support for innovative drugs, which is expected to promote healthy development across various segments of the pharmaceutical industry [6][32]. - The report emphasizes a positive outlook for the pharmaceutical sector, particularly in the context of recent government policies aimed at enhancing healthcare services and drug innovation [27][32]. Summary by Sections Weekly Market Review - The pharmaceutical and biotechnology index rose by 2.02%, outperforming the CSI 300 index by 0.64 percentage points, ranking 18th in industry performance [9]. - Year-to-date, the index has increased by 6.53%, again surpassing the CSI 300 by 6.3 percentage points, ranking 14th [9]. - Sub-sectors such as medical services and medical devices showed significant gains, with medical services up 3.7% and medical devices up 3.29% for the week [13]. Individual Stock Performance - In the A-share market, 321 out of 477 pharmaceutical stocks rose, with notable gainers including Hotgen Biotech (+38.63%) and Berry Genomics (+34.39%) [18]. - In the Hong Kong market, 78 out of 106 pharmaceutical stocks increased, with top performers being HeartFlow Medical-B (+31.87%) and Hengrui Medicine-B (+30.19%) [22]. Industry News and Policies - The government work report highlighted the need for a collaborative approach to healthcare, emphasizing the integration of medical services, insurance, and pharmaceuticals [27]. - Key policies include optimizing drug procurement, enhancing quality assessments, and increasing financial support for basic medical insurance [33]. Weekly Insights - The report reiterates a bullish stance on the pharmaceutical sector, particularly in light of government initiatives to support innovative drug development and improve healthcare financing [32][34]. - Specific recommendations include focusing on companies in various segments such as raw materials, chemical preparations, and medical services, with suggested stocks like Hengrui Medicine and WuXi AppTec [34].

一、公司回购股份的进展情况 截至2023年11月30日，公司通过股份回购专用证券账户以集中竞价交易方式回购公 司股份数量为5,745,900股，占公司目前总股本的比例1.04%，最低成交价格为10.09元/ 股，最高成交价格为11.83元/股，成交总金额为人民币61,446,931.83元（不含交易费 用），本次回购符合公司回购方案。 | 证券代码：300401 | 证券简称：花园生物 | 公告编号：2023-068 | | --- | --- | --- | | 债券代码：123178 | 债券简称：花园转债 | | 浙江花园生物医药股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江花园生物医药股份有限公司（以下简称"公司"）于2023年8月22日召开第六 届董事会第十六次会议和第六届监事会第十四次会议，并于2023年9月7日召开2023年第 一次临时股东大会，审议通过了《关于回购公司部分股份方案的议案》。公司拟使用自 有资金不低于人民币10,000万元（含）且不超过人民币20,000万元（含）以集中竞价交 易方式 ...